Sign In
Buy IFRX
$1.70
-0.0200 (-1.16%)
At Close: Jul 31, 2026
Reviewing Athira Pharma (NASDAQ:ATHA) & InflaRx (NASDAQ:IFRX)
01:31am, Friday, 27'th Mar 2026
InflaRx (NASDAQ: IFRX - Get Free Report) and Athira Pharma (NASDAQ: ATHA - Get Free Report) are both small-cap medical companies, but which is the better investment? We will compare the two companies
InflaRx N.V. (IFRX) Reports Q4 Loss, Lags Revenue Estimates
09:46am, Thursday, 19'th Mar 2026
InflaRx N.V. (IFRX) came out with a quarterly loss of $0.17 per share versus the Zacks Consensus Estimate of a loss of $0.18.
InflaRx Reports Full Year 2025 Results and Highlights Key Achievements and Expected Milestones
07:30am, Thursday, 19'th Mar 2026
Promising Phase 2a data announced for izicopan, underscoring its potential as a meaningfully differentiated, effective and safe oral inhibitor of C5aR Substantial progress made toward Phase 2b readine
JENA, Germany, March 18, 2026 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced
InflaRx Announces Receipt of Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement
05:00pm, Friday, 13'th Mar 2026
JENA, Germany, March 13, 2026 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced
InflaRx to Report Full Year 2025 Results on March 19, 2026
07:30am, Thursday, 12'th Mar 2026
JENA, Germany, March 12, 2026 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced
InflaRx Announces Participation in the Leerink Partners Global Healthcare Conference
07:30am, Thursday, 26'th Feb 2026
JENA, Germany, Feb. 26, 2026 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced
InflaRx Announces Participation in February Investor Conferences
07:30am, Thursday, 29'th Jan 2026
JENA, Germany, Jan. 29, 2026 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced
InflaRx N.V. (NASDAQ:IFRX) Receives Consensus Rating of “Moderate Buy” from Analysts
05:24am, Sunday, 11'th Jan 2026
Shares of InflaRx N.V. (NASDAQ: IFRX - Get Free Report) have received a consensus rating of "Moderate Buy" from the eight brokerages that are currently covering the stock, MarketBeat reports. One anal
InflaRx Announces Strategy Focused on Capital-Efficient Execution with Izicopan and Near-Term Value Creation
08:00am, Thursday, 08'th Jan 2026
InflaRx to prioritize izicopan as its leading pipeline asset, with a goal of continuing toward Phase 2b readiness in hidradenitis suppurativa (HS) To broaden signal-finding activities for izicopan in
InflaRx Reopens Case For Axed Phase 3 Drug For Rare Skin Disorder
07:08am, Monday, 05'th Jan 2026
InflaRx presented data analyses from a terminated Phase 3 study on the potential treatment for rare skin condition.
InflaRx Provides Update on Phase 3 Data Analyses for Vilobelimab in Pyoderma Gangrenosum
07:30am, Tuesday, 30'th Dec 2025
While the Phase 3 trial of vilobelimab in ulcerative pyoderma gangrenosum (PG) was terminated earlier this year due to futility regarding its prespecified primary endpoint (as previously disclosed), s
InflaRx Announces International Nonproprietary Name of “Izicopan” for INF904
07:30am, Thursday, 11'th Dec 2025
JENA, Germany, Dec. 11, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced
InflaRx N.V. (IFRX) Discusses Topline Phase 2a Data in Chronic Spontaneous Urticaria and Hidradenitis Suppurativa Transcript
02:41pm, Monday, 10'th Nov 2025
InflaRx N.V. ( IFRX ) Discusses Topline Phase 2a Data in Chronic Spontaneous Urticaria and Hidradenitis Suppurativa November 10, 2025 8:00 AM EST Company Participants Jan Medina - Head of Investor Rel
InflaRx Reports Positive Phase 2a Data for INF904 in Hidradenitis Suppurative (HS) and Chronic Spontaneous Urticaria (CSU)
07:30am, Monday, 10'th Nov 2025
Phase 2a data support oral C5aR inhibitor INF904 as a potentially transformational and best-in-class immunomodulatory agent, indicating strong potential for efficacy and no safety signals of concern I
